<span item_type="fundamental" item_id="9a756e8da6893d8f93a0d7b86676f9c6" counter_id="ST/US/OLMA" env="prod"></span><span item_type="announcement" item_id="581212570990284801" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.49, missing the estimate of USD -0.4704.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -49.53 M.</p><p></p><h3>Operating Expenses</h3><ul><li><strong>Research and Development Expenses</strong>: For the three months ended September 30, 2025, research and development expenses were $39.951 million, an increase from $33.226 million for the same period in 2024, primarily due to higher spending on clinical development activities and personnel-related costs, partially offset by a decrease in stock-based compensation expense.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm"></span></li><li><strong>General and Administrative Expenses</strong>: For the three months ended September 30, 2025, general and administrative expenses were $5.926 million, up from $4.395 million for the same period in 2024, primarily due to higher corporate-related costs and an increase in stock-based compensation expense.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm"></span></li></ul><h3>Other Income</h3><ul><li><strong>Interest Income</strong>: For the three months ended September 30, 2025, interest income was $3.648 million, compared to $2.928 million for the same period in 2024, reflecting increased interest income from investments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm"></span></li></ul><h3>Net Loss</h3><ul><li><strong>Net Loss</strong>: For the three months ended September 30, 2025, the net loss was $42.217 million, compared to $34.555 million for the same period in 2024, primarily due to increased operating expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the nine months ended September 30, 2025, net cash used in operating activities was - $108.389 million, compared to - $78.067 million for the same period in 2024, primarily due to increased research and development expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: For the nine months ended September 30, 2025, net cash provided by investing activities was $6.424 million, compared to $20.898 million for the same period in 2024, primarily due to maturities of marketable securities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm"></span></li><li><strong>Net Cash Used in Financing Activities</strong>: For the nine months ended September 30, 2025, net cash used in financing activities was - $2.255 million, compared to net cash provided by financing activities of $24.518 million for the same period in 2024, reflecting issuance costs related to the 2024 Private Placement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Olema Pharmaceuticals, Inc. plans to continue advancing its lead product candidate, palazestrant, through late-stage clinical development both as a monotherapy and in combination with other targeted agents. The company anticipates top-line results for its pivotal Phase 3 clinical trial, OPERA-01, in the second half of 2026, with a potential FDA approval and commercial launch in late 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm"></span></li><li><strong>Non-Core Business</strong>: The company is also developing OP-3136, a KAT6 inhibitor, with initial clinical results expected in mid-2026. Olema plans to expand its operations and increase its headcount to support ongoing research and development activities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm"></span></li></ul>

Olema Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0